Press Coverage
PRESS
Life Science Nation Launches First Coast Healthtech Week Creating A 3 Day Funding and Investment Event for Research, Preclinical, Seed and Series A or B Startups
May 25, 2018 – Life Science Nation (LSN) launches a new early stage global investor conference called First Coast Healthtech Week, September 5-7th in Boston, MA. The new annual event will expand access to the earliest stage companies, not yet on global investors’ radar. This includes companies within the healthcare industry across the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA essentially the North East Corridor.
LSN’s established network of over 5,000 early stage global investors want to be the first to discover the latest technological advances in the healthcare industry. With regular attendance to the RESI Conference Series they source, engage and allocate funds to startup firms across the silos of biotech, medtech, diagnostics, and digital health. Still, they are seeking out more compelling investment opportunities.
“The First Coast is blessed with an amazing amount of technological assets addressing unmet medical needs across the entire healthcare spectrum. They need to get in front of global investors,” says Dennis Ford, CEO at Life Science Nation. This includes over 100 incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs each with aggregate portfolios of 1000 or more assets.
According to BioWorld, barely five months into 2018, investors have placed more seed and series A money into biotherapeutics companies than all of last year. The challenge is matching new early stage global investor mandates with the right early stage companies that are a fit. LSN intends to fix the gap in funding through the First Coast initiative.
Chuck Stetson, CEO, Stetson Family Office is a Title Sponsor of the Healthtech Innovators Investor Summit, day 1 conference and the day 2 RESI Global Investor Conference. Chuck is pioneering a new, nonprofit, evergreen, endowment model for early stage global companies within technology rich innovation hubs. “It is time to address the developmental valley of death and muster state of the art resources to bring breakthrough technologies to market faster,” Stetson stated.
LSN invites the technology hubs and their scientist entrepreneurs of the First Coast to take advantage of this inaugural launch. LSN created an affordable registration price that will facilitate more startups attending the three-day event. “We had to get the price point right as the early stage folks have been priced out of most of the other conferences” said Ford. Register for the event at First Coast Healthtech Week.
Qualifying First Coast day 1 registrants are the north east corridor incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs and their constituents and the investors and partners that seek them. Day 2 and 3 are open to all global attendee’s scientist/entrepreneurs, fund raising CEOs, investors, channel partners and service providers.
About Life Science Nation
Life Science Nation is a global matching platform for early stage buyers and sellers across the domains of Biotech, Medtech, Diagnostics and Digital Health. LSN curates two databases: a buy-side of global early stage investors and a sell-side of global technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel and pipeline development.
LSN owns and operates the Redefining Early Stage Investments (RESI) Conference that is held five times a year in San Francisco, Toronto, Boston and New York City (soon to expand to Europe and Asia). Just recently LSN launched the First Coast Healthtech Week an annual conference expanding its focus to healthcare innovation hubs and even earlier stage technologies.
About Stetson Family Office
Stetson Family Office formed in 1919 is dedicated to building a better healthcare private equity ecosystem for getting the best of the best healthcare ideas from the research laboratory to commercialization by:
May 25, 2018 – Life Science Nation (LSN) launches a new early stage global investor conference called First Coast Healthtech Week, September 5-7th in Boston, MA. The new annual event will expand access to the earliest stage companies, not yet on global investors’ radar. This includes companies within the healthcare industry across the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA essentially the North East Corridor.
LSN’s established network of over 5,000 early stage global investors want to be the first to discover the latest technological advances in the healthcare industry. With regular attendance to the RESI Conference Series they source, engage and allocate funds to startup firms across the silos of biotech, medtech, diagnostics, and digital health. Still, they are seeking out more compelling investment opportunities.
“The First Coast is blessed with an amazing amount of technological assets addressing unmet medical needs across the entire healthcare spectrum. They need to get in front of global investors,” says Dennis Ford, CEO at Life Science Nation. This includes over 100 incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs each with aggregate portfolios of 1000 or more assets.
According to BioWorld, barely five months into 2018, investors have placed more seed and series A money into biotherapeutics companies than all of last year. The challenge is matching new early stage global investor mandates with the right early stage companies that are a fit. LSN intends to fix the gap in funding through the First Coast initiative.
Chuck Stetson, CEO, Stetson Family Office is a Title Sponsor of the Healthtech Innovators Investor Summit, day 1 conference and the day 2 RESI Global Investor Conference. Chuck is pioneering a new, nonprofit, evergreen, endowment model for early stage global companies within technology rich innovation hubs. “It is time to address the developmental valley of death and muster state of the art resources to bring breakthrough technologies to market faster,” Stetson stated.
LSN invites the technology hubs and their scientist entrepreneurs of the First Coast to take advantage of this inaugural launch. LSN created an affordable registration price that will facilitate more startups attending the three-day event. “We had to get the price point right as the early stage folks have been priced out of most of the other conferences” said Ford. Register for the event at First Coast Healthtech Week.
Qualifying First Coast day 1 registrants are the north east corridor incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs and their constituents and the investors and partners that seek them. Day 2 and 3 are open to all global attendee’s scientist/entrepreneurs, fund raising CEOs, investors, channel partners and service providers.
About Life Science Nation
Life Science Nation is a global matching platform for early stage buyers and sellers across the domains of Biotech, Medtech, Diagnostics and Digital Health. LSN curates two databases: a buy-side of global early stage investors and a sell-side of global technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel and pipeline development.
LSN owns and operates the Redefining Early Stage Investments (RESI) Conference that is held five times a year in San Francisco, Toronto, Boston and New York City (soon to expand to Europe and Asia). Just recently LSN launched the First Coast Healthtech Week an annual conference expanding its focus to healthcare innovation hubs and even earlier stage technologies.
About Stetson Family Office
Stetson Family Office formed in 1919 is dedicated to building a better healthcare private equity ecosystem for getting the best of the best healthcare ideas from the research laboratory to commercialization by:
- Building sustainable endowment financing for life science accelerators that are providing a better risk-mitigation mechanism to attract angel, venture and family office private equity capital to life sciences.
- Fostering collaboration between centers of life science innovation which is currently not occurring.